Aurora Cannabis (NASDAQ:ACB) Stock

Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.

Aurora Cannabis Inc

Ace Global Business Acquisition Ltd

Ace Global Business Acquisition Ltd Units (1 Ord & 1 War)

Ace Global Business Acquisition Ltd Warrants (26/03/2026)

ALBINA COMMUNITY BNCRP by Albina Community Bancorp

Annabidiol Corp

ARCO BIOMEDICAL CO LTD by Acro Biomedical Co., Ltd.

Acro Biomedical Co Ltd

The Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications&nbsp;&nbsp;&nbsp;
Primary endpoint of the study was met of increasing systolic blood pressure and demonstration of other benefits including no increase in heart rate and preserved renal function
Partnership discussions with multiple potential partners that may fund the remainder of clinical development thus eliminating the Company's cash burn with the cardiovascular pipeline
Phase 2 SEISMiC C interim data results targeted for July
Final stages of protocol design for Phase 3 in acute heart failure indication for China nearly complete for regional license partner and will be fully funded by the licensee
WARRINGTON, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries, announced that the istaroxime early cardiogenic shock Phase 2 study called SEISMiC B is published in the Journal of Heart and Lung Transplantation and is available on the journal website. The publication is entitled "Safety and Efficacy Intravenous Istaroxime up to 60 hours for Patients with Pre-Cardiogenic Shock.1" Patients with this condition have poor cardiac function, low blood pressure and need rapid treatment.
The article notes in the SEISMiC B study that istaroxime significantly increased blood pressure over the first six hours of treatment and persisted for 60 hours. Patients also had significantly improved cardiac output, decreased pulmonary capillary wedge pressure (a measure of fluid back up), no increase in heart rate, no increase in clinically significant arrythmias and preserved renal function, a very unique profile of potential beneficial effects for this patient population.
An accompanying editorial highlighted the encouraging results and described istaroxime as, "a potential new approach to heart failure-cardiogenic shock in which the next frontier is not just survival, but earlier and smarter stabilization.2"
Istaroxime has completed four positive Phase 2 studies, including two in early cardiogenic shock (called SCAI Stage B). Market research conducted by the Company with U.S. based clinical cardiologists reveals a high desire for cardiogenic shock drug treatment innovation.

Biotech

News

General

WINT

Windtree Therapeutics' Istaroxime Achieves Success In Phase 2 SEISMiC B Study, Meeting Primary Endpoint And Showing Cardiogenic Shock Benefits Without Increasing Heart Rate Or Renal Risk

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/06/13/final-trades-alphabet-unitedhealth-schlumberger-and-the-iye.html">Halftime Report Final Trades</a>,&#8221; Rob Sechan, CEO of NewEdge Wealth, recommended buying Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>). The stock has been the best performer in the Magnificent Seven over the past month and <a href="https://www.benzinga.com/markets/tech/25/06/45899809/ericsson-google-cloud-launch-new-tool-to-help-telecoms-build-faster-smarter-networks">is the cheapest as well.</a>
As per recent news, Ericsson announced on June 12 the launch of Ericsson On-Demand, a new solution delivering core network services as a true software-as-a-service (SaaS) platform to communications service providers (CSPs). The platform is designed with Alphabet Google Cloud, leveraging AI infrastructure and Google Kubernetes Engine (GKE), and is managed end-to-end by Ericsson.
Shannon Saccocia, CFA, is the chief investment officer of NB Private Wealth, named iShares U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYE#NYSE">IYE</a>) as her final trade.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage her</a>e
Sarat Sethi, DCLA managing partner and portfolio manager, picked Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) as his final trade.
On the earnings front, Schlumberger reported worse-than-expected first-quarter 2025 results on April 25. Revenue declined 3% year over year to $8.49 billion, missing estimates of $8.59 billion. Adjusted EPS slid 4% to 72 cents, missing the consensus of 74 cents.
Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, said UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is a good trade from here.
As per recent news, UnitedHealth Group re-elected all current directors on June 4. The board authorized the payment of a cash dividend of $2.21 per share, up from the prior dividend of $2.10, to be paid on June 24 to common stock shareholders of record as of the close of business on June 16.
Price Action:
<ul class="wp-block-list">
<li>Alphabet shares fell 0.6% to close at $174.67 on Friday.</li>
<li>iShares U.S. Energy ETF rose 1.8% during the session.</li>
<li>UnitedHealth shares fell 1.6% to settle at $313.53 on Friday.</li>
<li>SLB shares gained 1.9% to settle at $36.30 during the session.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june">Top 2 Energy Stocks That May Fall Off A Cliff in June</a></li>
</ul>
Photo: Shutterstock

Markets

Media

Trading Ideas

GOOG

GOOGL

iShares Dow Jones US Energy Sector Index Fund

UnitedHealth Group, Schlumberger, Alphabet And More On CNBC's 'Final Trades'

Natural Gas Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced that Stephen C. Taylor has transitioned from Chairman of the Board to the role of Chairman Emeritus, effective immediately. Concurrently, the Company's Board of Directors has appointed Donald J. Tringali as Chairman. Mr. Taylor continues his role as a director on the Company's Board.

Management

Natural Gas Services Appoints Donald Tringali As Chairman; Says Stephen Taylor Transitioned From Chairman Of Board To Chairman Emeritus, Effective Immediately

Refinements to probe configuration and proprietary algorithms are expected to drive substantial improvements in MRI-PDFF correlation
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54274068&amp;newsitemid=20250616575045&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=d3b8793be6994cca89b77baa3171adab">ENDRA Life Sciences Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>), a pioneer in imaging technologies for the early detection and monitoring of metabolic liver disease, today announced that its ongoing multisite pilot study has helped to identify several product enhancements to further improve the performance of its TAEUS&#xAE; Liver system against the gold standard, MRI. These findings are expected to drive substantial improvements to the device's probe design and proprietary algorithms, measurably improving diagnostic accuracy and repeatability. These enhancements are currently being implemented and are expected to strengthen the outcomes of the Company's planned U.S. Food and Drug Administration ("FDA") De Novo pivotal study.
Consistent with its revamped go-to-market strategy, ENDRA is conducting a multisite clinical initiative designed to bolster the diagnostic performance of TAEUS Liver prior to initiation of the FDA pivotal study. In collaboration with several leading imaging centers, the Company has collected liver fat measurement data from more than 100 subjects that compare TAEUS scans against MRI-PDFF.

NDRA

ENDRA Life Sciences Announces That Its Ongoing Multisite Pilot Study Has Helped To Identify Several Product Enhancements To Further Improve The Performance Of Its TAEUS Liver System Against The Gold Standard, MRI

NITO

N2OFF Increases Investment In Melz Project To Explore Integrating Additional 40-60 MW Battery Storage

<ul>
<li>The test, run on Abbott's portable i-STAT&#xAE; Alinity&#xAE; instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), otherwise known as concussion</li>
<li>The test produces lab-quality results in 15 minutes</li>
<li>Clinicians can get a result at the patient's bedside, making the test accessible at urgent care clinics and healthcare settings outside of the hospital emergency room</li>
<li>The test can be used to help evaluate patients up to 24 hours after injury</li>
</ul>
MISSISSAUGA, ON, June 16, 2025 /CNW/ -- Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) announced today that Health Canada has approved the company's&nbsp;i-STAT TBI test cartridge for use with whole blood, helping clinicians to assess suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes. Previously, the tests used to help assess mild traumatic brain injury (mTBI) were only authorized for use with plasma or serum, requiring samples to be sent to a lab for processing.

Health Canada Approves Abbott's i-STAT TBI Test Cartridge For Use With Whole Blood, To Assess Suspected Concussion At Patient's Bedside And Obtain Lab-Quality Results In 15 Minutes

Achievement demonstrates manufacturer's drive for excellence in drone production&nbsp;
Cheseaux-sur-Lausanne, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#NYSE">UAVS</a>), a leading provider of advanced drone and aerial imaging solutions, is proud to announce their Switzerland facility has been recommended to receive ISO 9001 certification by third-party auditors following an intensive review of the facilities Quality Management System. This prestigious certification reflects AgEagle's commitment to excellence, safety, and innovation.
The ISO 9001 standard is widely recognized across all industries and sets rigorous requirements for quality management, customer satisfaction, risk mitigation, safety, and continuous improvement. Earning this certification for the Switzerland facility—home to key research, development, and manufacturing of AgEagle's cutting-edge drone technologies—demonstrates:
<ul>
<li>Unmatched Quality Assurance: The facility meets the highest industry standards for producing reliable drone systems, such as the eBee TAC Public Safety drone and the eBee VISION drone, ensuring precision and performance for worldwide customers. &nbsp;</li>
<li>Operational Excellence: The process highlights AgEagle's dedication to streamlining production and maintaining safety, supporting sustainable farming innovations and bringing new technologies to market &nbsp;</li>
<li>Enhanced Global Trust: Certification strengthens AgEagle's credibility with international clients, including governments and procurement agencies, aligning with the company's growth into Intelligence, Surveillance and Reconnaissance (ISR) marketplaces and public safety operators. &nbsp;</li>
</ul>

UAVS

AgEagle Aerial Systems' Switzerland Facility Recommended To Receive ISO 9001 Certification By Third-Party Auditors Following An Intensive Review Of The Facilities Quality Management System

XAIR

Beyond Air Submits A Premarket Approval Supplement Application To The FDA For LungFit PH II

<h3>Gainers</h3>
<ul>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares rose 20.9% to $11.14 during Monday's pre-market session. The company's market cap stands at $7.7 million. </li>
<li>Twin Hospitality Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWNP#NASDAQ">TWNP</a>) shares rose 20.07% to $6.04. The company's market cap stands at $346.1 million. </li>
<li>Yunji (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) shares rose 14.18% to $1.9. The company's market cap stands at $37.3 million. </li>
<li>ZHONGCHAO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) shares moved upwards by 13.0% to $1.3. The market value of their outstanding shares is at $32.8 million. </li>
<li>Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) stock increased by 12.14% to $1.2. The market value of their outstanding shares is at $16.5 million. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) shares increased by 9.65% to $1.59. The company's market cap stands at $27.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fitell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) stock declined by 16.8% to $0.38 during Monday's pre-market session. The company's market cap stands at $7.5 million. </li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) shares declined by 10.33% to $1.39. The company's market cap stands at $15.3 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) shares decreased by 7.55% to $1.96. The market value of their outstanding shares is at $6.0 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) stock declined by 7.26% to $0.11. The company's market cap stands at $5.5 million. </li>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares declined by 6.36% to $0.36. The market value of their outstanding shares is at $25.7 million. </li>
<li>LiveWire Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NYSE">LVWR</a>) shares decreased by 5.47% to $5.36. The company's market cap stands at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

FTEL

JZXN

LVWR

NAAS

SBET

TWNP

ZCMD

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares rose 37.5% to $9.21 during Monday's pre-market session. The company's market cap stands at $576.7 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares increased by 37.43% to $0.03. The company's market cap stands at $11.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares increased by 20.58% to $0.39. The company's market cap stands at $11.8 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares increased by 17.21% to $5.48. The market value of their outstanding shares is at $2.8 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) shares rose 15.89% to $1.75. The market value of their outstanding shares is at $59.1 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares rose 15.49% to $0.13. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock decreased by 39.8% to $21.79 during Monday's pre-market session. The market value of their outstanding shares is at $2.1 billion. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) stock decreased by 11.51% to $1.0. The market value of their outstanding shares is at $33.1 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares fell 11.21% to $0.32. The company's market cap stands at $4.0 million. </li>
<li>Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) stock declined by 9.36% to $0.25. The company's market cap stands at $8.4 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) stock declined by 7.69% to $1.32. The market value of their outstanding shares is at $23.1 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock fell 7.39% to $0.61. The company's market cap stands at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APDN

BEAT

BFRI

CODX

HCTI

IMNN

JUNS

NCNA

ONMD

SAGE

SRPT

VTAK

12 Health Care Stocks Moving In Monday's Pre-Market Session

Crown Holdings To Promote Djalma Novaes Jr., To EVP And COO, Effective July 1, 2025

PHAT

Phathom Pharmaceuticals Announces FDA Updated The Orange Book To Reflect The 10-Year Period Of Non-Patent New Chemical Entity Exclusivity For VOQUEZNA

Critical Metals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) ("Critical Metals Corp" or the "Company"), a leading critical minerals mining company, today announced that it has received a Letter of Interest from the Export-Import Bank of the United States (EXIM), for a total non-dilutive funding package of $120 million. This funding package from the U.S's official export credit agency is expected to be used to develop the Tanbreez Project, one of the world's largest rare earth deposits located in Greenland.
Based on preliminary information submitted by Critical Metals Corp for the Tanbreez Project, EXIM will consider financing up to $120 million of the project's costs with a repayment term of 15 years under EXIM's new Supply Chain Resiliency Initiative (SCRI). The amount of funding is expected to be sufficient for Critical Metals Corp to complete necessary technical and economic studies, pre-production activities, and begin mining at the Tanbreez Project.
The Company expects that the Tanbreez Project will require $290 million in capital expenditure to bring it to initial commercial production. In its initial commercial production phase, the Company expects that the Tanbreez Project will be capable of producing up to 85,000 metric tons of rare earth material annually.

Contracts

CRML

Critical Metals Corp Secures $120M Non-Dilutive Funding Letter Of Interest From U.S. Export-Import Bank To Advance Greenland's Tanbreez Rare Earth Project Under Supply Chain Resiliency Initiative

<h3>Gainers</h3>
<ul>
<li>OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) shares increased by 103.7% to $3.28 during Monday's pre-market session. The company's market cap stands at $24.6 million. </li>
<li>AIRO Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRO#NASDAQ">AIRO</a>) shares increased by 32.41% to $31.78. The company's market cap stands at $791.4 million. </li>
<li>Ming Shing Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSW#NASDAQ">MSW</a>) stock moved upwards by 13.13% to $4.87. The market value of their outstanding shares is at $63.1 million. </li>
<li>OFA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFAL#NASDAQ">OFAL</a>) stock increased by 12.83% to $1.75. The market value of their outstanding shares is at $24.3 million. </li>
<li>SUNation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) stock rose 9.43% to $1.74. The company's market cap stands at $5.9 million. </li>
<li>SKYX Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYX#NASDAQ">SKYX</a>) stock increased by 9.09% to $1.32. The market value of their outstanding shares is at $141.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) stock fell 24.1% to $0.23 during Monday's pre-market session. The market value of their outstanding shares is at $2.1 million. </li>
<li>Icon Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICON#NASDAQ">ICON</a>) stock declined by 18.84% to $2.37. The company's market cap stands at $5.1 million. </li>
<li>KULR Technology Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) shares decreased by 16.39% to $0.96. The market value of their outstanding shares is at $293.8 million. </li>
<li>Robin Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) stock decreased by 14.34% to $11.99. The company's market cap stands at $28.6 million. </li>
<li>Energys Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGS#NASDAQ">ENGS</a>) shares fell 13.51% to $2.08. The market value of their outstanding shares is at $29.7 million. </li>
<li>Phoenix Asia Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHOE#NASDAQ">PHOE</a>) stock declined by 11.89% to $4.15. The company's market cap stands at $89.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRO

DFLI

ENGS

ICON

KULR

OFAL

PHOE

RBNE

SKYX

SUNE

12 Industrials Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Neonode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEON#NASDAQ">NEON</a>) shares increased by 19.0% to $20.0 during Monday's pre-market session. The company's market cap stands at $335.6 million. </li>
<li>Coda Octopus Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODA#NASDAQ">CODA</a>) shares moved upwards by 15.78% to $8.95. The market value of their outstanding shares is at $100.5 million. As per the press release, Q2 earnings came out today. </li>
<li>BTCS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) shares rose 12.69% to $2.45. The company's market cap stands at $51.5 million. </li>
<li>Maris Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEK#NASDAQ">MTEK</a>) stock moved upwards by 12.09% to $3.43. The market value of their outstanding shares is at $27.0 million. </li>
<li>PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) stock rose 10.11% to $4.9. The market value of their outstanding shares is at $649.2 million. The company's, Q4 earnings came out today. </li>
<li>Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) stock increased by 9.35% to $146.05. The company's market cap stands at $32.5 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock decreased by 16.1% to $0.72 during Monday's pre-market session. The company's market cap stands at $7.1 million. </li>
<li>XTI Aerospace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) stock fell 15.28% to $3.44. The company's market cap stands at $21.6 million. </li>
<li>Creative Global Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTL#NASDAQ">CGTL</a>) stock fell 7.15% to $1.17. The market value of their outstanding shares is at $25.0 million. </li>
<li>Nortech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) shares fell 7.11% to $8.5. The company's market cap stands at $23.4 million. </li>
<li>Materialise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTLS#NASDAQ">MTLS</a>) stock fell 6.61% to $5.09. The market value of their outstanding shares is at $300.6 million. </li>
<li>SmartKem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTK#NASDAQ">SMTK</a>) stock declined by 5.27% to $1.08. The market value of their outstanding shares is at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIOT

BTCS

CGTL

CODA

CRCL

MLGO

MTEK

MTLS

NEON

NSYS

SMTK

XTIA

12 Information Technology Stocks Moving In Monday's Pre-Market Session

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16090330/Jinjiang.jpeg" alt="" class="wp-image-14436" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16090330/Jinjiang.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16090330/Jinjiang-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16090330/Jinjiang-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
Three years after privatizing its Hong Kong-listed shares, storied hotelier Jin Jiang has rolled out plans to re-list on the city's stock exchange
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Jin Jiang has applied to list in Hong Kong, just three years after withdrawing from the market</li>
<li>The company's profit tumbled over 80% in the first quarter as Chinese travelers reined in their spending</li>
</ul>
The opening chapter of "Romance of the Three Kingdoms," one of China's four great classical novels, says the world operates in cycles of long periods of division, followed by reunification, before more division.
That same rule applies in the capital market these days to&nbsp;Jin Jiang Capital Co. Ltd.&nbsp;The company, one of China's three largest hoteliers, checked out of the Hong Kong stock market three years ago with its privatization, believing its shares were undervalued. But now its 45%-owned company, the similarly named&nbsp;Shanghai Jin Jiang International Hotels Co. Ltd.&nbsp;(600754.SH), is saying it plans to make a second listing in Hong Kong and has hired KPMG as its auditor, according to&nbsp;<a href="https://static.sse.com.cn/disclosure/listedinfo/announcement/c/new/2025-06-05/600754_20250605_NDUX.pdf">a filing</a>&nbsp;with the Shanghai Stock Exchange earlier this month.
Jin Jiang is one of China's most storied hotel brands, with a portfolio that includes some of Shanghai's most famous properties, such as its namesake art deco-style Jin Jiang Hotel, the Peace Hotel, formerly known as the Cathay Hotel, and the newer Park Hotel. When U.S. President Richard Nixon visited China in 1972, his U.S. delegation stayed at the Jin Jiang Hotel.
Jin Jiang International listed in Shanghai in 1994, just years after China launched its first stock exchanges. Its controlling shareholder, Jin Jiang Capital, went public in Hong Kong in 2006 and delisted in 2022. The new Hong Kong listing attempt for Jin Jiang International, just three years after Jin Jiang Capital's exit, has left investors wondering why the company is coming back for a second stay, and whether the new listing may be worth considering.
To figure out what's happening, we'll rewind to 2021 and examine why Jin Jiang Capital delisted in the first place. Disclosures from that time show its privatization was driven by two main factors. Back then, the company said its Hong Kong shares were consistently valued lower than its peers, which was compounded by low trading volumes. Additionally, the company believed that privatizing could help to cut costs, boosting its operating efficiency.
<h4 class="wp-block-heading">Low trading volumes</h4>
So, if the company withdrew from Hong Kong due to low valuations and trading volumes, why does it feel the same thing won't happen again?
The biggest Hong Kong-listed hotel stock is&nbsp;H World Group&nbsp;(1179.HK; HTHT.US), whose daily trading volume averages 1 million to 2 million shares typically worth HK$50 million ($6.37 million) or less.&nbsp;Shangri-La Group's&nbsp;(0069.HK) daily volume averages several hundred thousand shares valued at several million Hong Kong dollars. Hongkong and Shanghai Hotels (0045.HK) is even worse, averaging less than 100,000 shares traded daily worth just several hundred thousand Hong Kong dollars, or tens of thousands of U.S. dollars.
The bottom line is that Hong Kong investors aren't easily excited by hotel stocks. In the year before Jin Jiang Capital's delisting, its average daily trading volume was around 1.8 million shares. Does the company have some major plans to bring more excitement to its stock this time around?
The timing of the relisting plan doesn't seem particularly good, either. Hong Kong stocks saw some terrific runs during Jin Jiang's first listing between 2006 and 2022, but the company never really took off during the hot periods.
Investors are far less confident these days than those earlier go-go years, worried about uncertainties created by geopolitical tensions and the ongoing China-U.S. trade war. While market sentiment has improved somewhat since late last year, daily trading volume in Hong Kong is still relatively muted, usually less than HK$200 billion. The overall environment in Hong Kong seems less friendly overall than during Jin Jiang's first Hong Kong listing.
<h4 class="wp-block-heading">Changing business strategies</h4>
Low valuation and trading volumes aside, Jin Jiang also listed cost-cutting as a major consideration behind its 2022 privatization. And yet now such consideration seems less important, since the company will once again incur all the costs associated with a Hong Kong listing. That raises of the question of what may have happened that has suddenly made a Hong Kong listing appealing again.
Perhaps the company really does have a new playbook now that didn't exist three years ago. Its disclosure says it has been strengthening ties with overseas capital markets to facilitate a future globalization strategy – a common theme recently among Chinese companies in search of growth as their home market slows.
Jin Jiang has been expanding overseas for more than a decade, with high-profile moves including its purchase of U.S.-based Interstate Hotels in 2009, which it later sold, and its acquisition of France's Louvre Hotels Group for a hefty 1.2 billion euros ($1.4 billion) in 2014. Those deals all happened during Jin Jiang Capital's first Hong Kong listing and show that global expansion isn't really anything new for the company.
<h4 class="wp-block-heading">Money-losing overseas business</h4>
Jin Jiang hasn't exactly been raking in the profits from its overseas business, either. Losses for that part of its operations have been piling up, totaling more than 200 million euros between 2020 and 2023. While the red ink has eased, the company's overseas business still lost 56.89 million euros last year. Louvre Hotels has been a big part of the problem, continuing to lose money a decade after the acquisition. With such a poor track record, how can Jin Jiang hope to convince Hong Kong investors of the big potential for more overseas expansion?
Things aren't much better at home. After benefiting from a wave of "revenge travel" in 2023, Jin Jiang and its peers have started to struggle as China's tourism recovery peters out. As that happens, the company's revenue fell 4% last year to 14.06 billion yuan from 2023 and its profit dropped 9% to 910 million yuan. The declines accelerated in this year's first quarter, with its revenue down 8.3% to 2.9 billion yuan and its profit tumbling 81% to 36.01 million yuan. Such plunging profits will hardly reel in investors.
The comeback listing may be Jin Jiang's way of striking while the iron is hot, since Hong Kong is now experiencing one of its best IPO markets in years. That means the company's shares might get a strong reception over the short haul from a rising tide that lifts all boats. But longer-term investors might be a harder sell and may want to observe the company for a year or two before swooping in to buy the stock on this second outing in Hong Kong.

Equities

IPOs

Global

Opinion

Checking Out Or Checking In? Jin Jiang Can't Decide

MODD

Modular Medical To Present GLP-1R Agonist Pump Delivery Data At ADA 85th Scientific Sessions

ADIL

Adial Pharmaceuticals Submits The Required Briefing Package To the FDA For The Upcoming End Of Phase 2 Meeting

Cantor Fitzgerald analyst Thomas Shinske initiates coverage on DeFi Development (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) with a Overweight rating and announces Price Target of $45.

Price Target

Initiation

Analyst Ratings

DFDV

Cantor Fitzgerald Initiates Coverage On DeFi Development with Overweight Rating, Announces Price Target of $45

MIST

Milestone Pharmaceuticals Submits A Response To FDA's CRL For CARDAMYST Nasal Spray Following Type A Meeting

Press Releases

Aurora Cannabis to Speak at the Global Cannabis Regulatory Summit

Aurora Cannabis Recognized for Executive Gender Diversity by The Globe and Mail

Aurora Cannabis Introduces the Company's First Inhalable Resin Cartridges for Patients in the United Kingdom

International Star Inc Announces New Engagement of T Bone Capital

Aurora Cannabis Announces the Completion of a Multimillion Dollar Investment and Renaming of B.C. Manufacturing Facility

Fintech

Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB

Rubicon Organics Announces Appointment of Glen Ibbott as Interim CFO

Aurora to Participate in TD Cowen's 9th Annual Future of the Consumer Conference

Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2025 Investor Conference Call and File Related Year End Information

Aurora Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22

Comments

Aurora Cannabis

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL